New hope for bile duct cancer: drug duo targets tough tumors

NCT ID NCT07649980

Not yet recruiting Disease control Sponsor: HuiKai Li Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—in 30 adults with advanced biliary tract cancer whose first treatment stopped working. The goal is to see if the combo can shrink tumors and improve survival. Participants receive the drugs by infusion every three weeks until the disease gets worse or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Becotatug vedotin (a targeted drug) combined with pucotenlimab (an immunotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced biliary tract cancer who have run out of standard options.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma of gallbladder and extrahepatic biliary tract biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER (BTC) EGFR-POSITIVE ADVANCED BILIARY TRACT CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.